Law360, New York (August 15, 2011, 6:58 PM ET) -- A Pennsylvania federal judge on Monday granted class certification to a group of indirect purchasers of Wellbutrin XL and its generic equivalent in a suit that accuses drugmakers Biovail Corp. and GlaxoSmithKline PLC of lodging baseless patent suits to delay the generic competition for the popular antidepressant.
U.S. District Judge Mary A. McLaughlin issued the order certifying the class of individuals who bought the drug in six U.S. states — California, Florida, Nevada, Tennessee, New York and Wisconsin. The certification follows a Thursday decision to grant class certification...
Indirect Purchasers Certified In Wellbutrin Antitrust Suit
To view the full article, take a free trial now.
